269 related articles for article (PubMed ID: 20378752)
41. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
42. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.
Bugarin C; Sarno J; Palmi C; Savino AM; te Kronnie G; Dworzak M; Shumich A; Buldini B; Maglia O; Sala S; Bronzini I; Bourquin JP; Mejstrikova E; Hrusak O; Luria D; Basso G; Izraeli S; Biondi A; Cazzaniga G; Gaipa G;
Haematologica; 2015 Jun; 100(6):e229-32. PubMed ID: 25862705
[No Abstract] [Full Text] [Related]
43. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.
Herold T; Schneider S; Metzeler KH; Neumann M; Hartmann L; Roberts KG; Konstandin NP; Greif PA; Bräundl K; Ksienzyk B; Huk N; Schneider I; Zellmeier E; Jurinovic V; Mansmann U; Hiddemann W; Mullighan CG; Bohlander SK; Spiekermann K; Hoelzer D; Brüggemann M; Baldus CD; Dreyling M; Gökbuget N
Haematologica; 2017 Jan; 102(1):130-138. PubMed ID: 27561722
[TBL] [Abstract][Full Text] [Related]
44. Characterization of CRLF2 Expression in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Rasekh EO; Atef AM; Khalil M; Ebeid E; Madney Y; Hamdy N
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491417
[TBL] [Abstract][Full Text] [Related]
45. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.
Russell LJ; Jones L; Enshaei A; Tonin S; Ryan SL; Eswaran J; Nakjang S; Papaemmanuil E; Tubio JM; Fielding AK; Vora A; Campbell PJ; Moorman AV; Harrison CJ
Genes Chromosomes Cancer; 2017 May; 56(5):363-372. PubMed ID: 28033648
[TBL] [Abstract][Full Text] [Related]
46. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Russell LJ; Capasso M; Vater I; Akasaka T; Bernard OA; Calasanz MJ; Chandrasekaran T; Chapiro E; Gesk S; Griffiths M; Guttery DS; Haferlach C; Harder L; Heidenreich O; Irving J; Kearney L; Nguyen-Khac F; Machado L; Minto L; Majid A; Moorman AV; Morrison H; Rand V; Strefford JC; Schwab C; Tönnies H; Dyer MJ; Siebert R; Harrison CJ
Blood; 2009 Sep; 114(13):2688-98. PubMed ID: 19641190
[TBL] [Abstract][Full Text] [Related]
47. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD; Reuther GW
Cancer Res; 2010 Oct; 70(19):7347-52. PubMed ID: 20807819
[TBL] [Abstract][Full Text] [Related]
48. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.
Palmi C; Savino AM; Silvestri D; Bronzini I; Cario G; Paganin M; Buldini B; Galbiati M; Muckenthaler MU; Bugarin C; Della Mina P; Nagel S; Barisone E; Casale F; Locatelli F; Lo Nigro L; Micalizzi C; Parasole R; Pession A; Putti MC; Santoro N; Testi AM; Ziino O; Kulozik AE; Zimmermann M; Schrappe M; Villa A; Gaipa G; Basso G; Biondi A; Valsecchi MG; Stanulla M; Conter V; Te Kronnie G; Cazzaniga G
Oncotarget; 2016 Sep; 7(37):59260-59272. PubMed ID: 27449287
[TBL] [Abstract][Full Text] [Related]
49. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
50. IKZF1
Kovach AE; Wengyn M; Vu MH; Doan A; Raca G; Bhojwani D
Pediatr Blood Cancer; 2024 Jul; 71(7):e30996. PubMed ID: 38637852
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
52. Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children.
Wang M; Wen J; Guo Y; Shen Y; An X; Hu Y; Xiao J
PLoS One; 2019; 14(12):e0224652. PubMed ID: 31830053
[TBL] [Abstract][Full Text] [Related]
53. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
54. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
55. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
56. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
57. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
58. Bilateral parotid gland swelling preceding the diagnosis of acute lymphoblastic leukemia with P2RY8-CRLF2 gene rearrangement.
Juan YT; Wang YL; Jaing TH
Pediatr Neonatol; 2023 May; 64(3):366-367. PubMed ID: 36967289
[No Abstract] [Full Text] [Related]
59. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A;
Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563
[TBL] [Abstract][Full Text] [Related]
60. Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
Potter N; Jones L; Blair H; Strehl S; Harrison CJ; Greaves M; Kearney L; Russell LJ
Leukemia; 2019 Apr; 33(4):893-904. PubMed ID: 30487598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]